after joining, you are assigned to receive either giai632 or a placebo. assignment is done by computer and you do not know which you receive.

the assignment determines which injection you will receive during the trial.

at the first visit, measurements of skin areas affected by vitiligo are recorded.

the facial vitiligo area scoring index (f‑vasi) and total vitiligo area scoring index (t‑vasi) are calculated to track changes over time.

photographs and questionnaires are taken to establish a starting point.

you receive a subcutaneous injection (under the skin) of the assigned product.

the product is a solution for injection; for giai632 the dose is listed as 00 df dosage form.

injections are given according to the study schedule and continue for the duration of the trial.

you continue to receive the same type of injection at regular intervals defined by the protocol.

the injections are administered until week 48, unless the study ends earlier for safety reasons.

each injection follows the same dose and route as the initial injection.

at weeks 12, 24, 36 and 48 you attend clinic visits for safety checks and efficacy assessments.

the same skin scoring indexes (f‑vasi and t‑vasi) are measured to determine the percentage change from baseline.

adverse events are recorded at each visit.

after week 48 an optional extension period may begin, allowing continued treatment and observation.

the same injection schedule and assessments are used during the extension.